PALO ALTO, Calif.--(BUSINESS WIRE)--Medable Inc., the leading software provider for decentralized clinical trials, and Datavant, the leader in helping healthcare organizations safely connect their data, today announced a partnership that will help clinical trial teams easily integrate multiple data sources to accelerate decentralized trial design, recruitment and data management.
Medable will integrate Datavant’s technology into Medable’s decentralized trials platform, allowing trial teams to combine real-world health records, claims, diagnostic and other data sources with their clinical trial data. This will eliminate various manual and time-intensive steps that slow down clinical trials, while also improving patient access and helping trial teams optimize evidence generation during and after studies.
“Making it easier to integrate multiple data sources is an important step in our mission to reduce clinical trial timelines by 50 percent,” said Dr. Michelle Longmire, CEO and co-founder of Medable. “Datavant provides us with a broad array of built-in connections to real-world data sources, which can now be combined to yield a more holistic view of patient health than clinical trial data alone.”
Datavant’s technology enables the linking of de-identified data across the entire patient journey, including electronic health records, claims, and diagnostics, as well as emerging sources such as genomics, wearable devices, socioeconomic and behavioral data and more. Datavant’s technology is already used by hundreds of organizations, including life sciences and medical device companies, academic medical centers, insurers and leading data aggregators and analytics companies. By linking real-world data sources with other sources of study data, clinical trial teams will be better equipped to generate and submit real-world evidence for regulatory assessment.
“Accelerating the pace of clinical development will help patients get access to life-saving therapies more quickly,” said Travis May, Datavant CEO. “We're excited to help power Medable's work in accelerating clinical trials by making it easier to connect to the ecosystem of real-world data.”
Medable started working together with Datavant earlier this year, as part of a multi-company research framework to accelerate the development of diagnostics and treatments for COVID-19. The ACCESS initiative—short for American COVID-19 Collaborative Enabling Seamless Science—provides a mobile application and secure infrastructure to connect health researchers and clinical trial teams securely with millions of home-bound individuals in the United States.
ACCESS makes it easy for individuals to contribute specific information about their COVID-19 experience, combine it with health records and data from wearable devices, and opt-in to participate in current and future studies for diagnostics, treatments, and vaccines. The data that people share can be quickly and anonymously matched to research studies, providing researchers with a foundational framework for dynamic research at scale.
Datavant’s mission is to connect the world’s health data to improve patient outcomes. Datavant works to reduce the friction of data sharing across the healthcare industry by building technology that protects the privacy of patients while supporting the linkage of de-identified patient records across datasets. Datavant is headquartered in San Francisco. Learn more about Datavant at www.datavant.com.
Medable is on a mission to get effective therapies to patients faster by transforming clinical drug development with disruptive technologies. The company’s digital platform streamlines design, recruitment, retention and data quality for decentralized trials, replacing siloed systems with integrated digital tools, data and interfaces to accelerate trial execution. Medable connects patients, sites and clinical trial teams to improve patient access, experience, and outcomes. Medable is a privately held, venture-backed company headquartered in Palo Alto, California. For more information, visit www.medable.com and follow @Medableinc on Twitter.